1625 Results (Page 2 of 65)
Rare Diseases Markets Research Reports
Spain Herpes Simplex Virus Therapeutics Market Analysis
Spain Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.
Canada Primary Hyperoxaluria (PH) Therapeutics Market Analysis
Canada Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
US Primary Hyperoxaluria (PH) Therapeutics Market Analysis
US Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
Brazil Primary Hyperoxaluria (PH) Therapeutics Market Analysis
Brazil Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
UK Primary Hyperoxaluria (PH) Therapeutics Market Analysis
UK Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
US Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
The US Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $1.9 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 9.3% during the forecast period of 2022-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favorable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma.
Spain Lysosomal Storage Disease Therapeutics Market Analysis
Spain lysosomal storage disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in this market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, Sigilon Therapeutics, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
India Von Willebrand Disease Therapeutics Market Analysis
India Von Willebrand Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.
Spain Interstitial Cystitis Therapeutics Market Analysis
Spain Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.
Spain Hypophosphatasia (HPP) Therapeutics Market Analysis
Spain hypophosphatasia (HPP) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for hypophosphatasia is anticipated to grow as a result of an increase in the ailment's prevalence, a family history of it, a robust product pipeline, and increased financing for research to create cutting-edge, new treatments for the condition. Major global players in the hypophosphatasia therapeutic market are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group Plc., Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc, Ultragenyx Pharmaceutical Inc, BioMarin Pharmaceutical Inc, Prior Company Ltd, Enobia Pharma Corporation, AstraZeneca Plc, Rallybio Corporation.
France Chronic Myelogenous Leukemia Therapeutics Market Analysis
France Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.
Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
Canada Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
Spain Hypertrophic Cardiomyopathy Therapeutics Market Analysis
Spain hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
France Chronic Lymphocytic Leukemia Therapeutics Market Analysis
France Chronic Lymphocytic Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A typical form of adult Leukemia known as chronic lymphocytic Leukemia (CLL) is characterized by an excessive production of aberrant white blood cells. In most cases, it happens when the bone marrow generates damaged cells, which interfere with the formation of antibodies and eventually render them ineffective against infections. The rise in chronic lymphocytic Leukemia cases is anticipated to fuel market expansion throughout the anticipated time frame. The market will rise as a result of the various treatment options available and the familial history of chronic lymphocytic leukemia. The high cost of treatment, however, is anticipated to limit market expansion. AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., MorphoSys AG, Ono Pharmaceutical Co., Ltd., and Amgen, Inc. are a few of the leading companies profiled in the chronic lymphocytic leukemia therapeutics market report.
Egypt Hepatorenal Syndrome Therapeutics Market Analysis
Egypt Hepatorenal Syndrome Therapeutics (HRS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Renal function improvement and halting further decline are the main objectives of treatment for hepatorenal syndrome. The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations amongst pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.
India Leukocyte Adhesion Deficiency (LAD-I) Market Analysis
India Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.
France Morquio Syndrome (MPS-IV) Therapeutics Market Analysis
France Morquio Syndrome (MPS-IV) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. As genetic illnesses like Morquio Syndrome (MPS-IV) has become more common, there is an increasing demand for specialised drugs to treat them. Major global players in Morquio Syndrome (MPS-IV) Therapeutics Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players.
Brazil Ankylosing Spondylitis Therapeutics Market Analysis
Brazil Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
France Lysosomal Storage Disease Therapeutics Market Analysis
France lysosomal storage disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in this market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, Sigilon Therapeutics, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
Spain Von Willebrand Disease Therapeutics Market Analysis
Spain Von Willebrand Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.
France Interstitial Cystitis Therapeutics Market Analysis
France Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.
Egypt Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis
Egypt Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.
France Hypophosphatasia (HPP) Therapeutics Market Analysis
France hypophosphatasia (HPP) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for hypophosphatasia is anticipated to grow as a result of an increase in the ailment's prevalence, a family history of it, a robust product pipeline, and increased financing for research to create cutting-edge, new treatments for the condition. Major global players in the hypophosphatasia therapeutic market are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group Plc., Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc, Ultragenyx Pharmaceutical Inc, BioMarin Pharmaceutical Inc, Prior Company Ltd, Enobia Pharma Corporation, AstraZeneca Plc, Rallybio Corporation.
UK Chronic Myelogenous Leukemia Therapeutics Market Analysis
UK Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.
France Hypertrophic Cardiomyopathy Therapeutics Market Analysis
France hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.